logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn files modified protocol for Leronlimab trial battling respiratory complications as a result of contracting Coronavirus

CytoDyn (OTCQB: CYDY) President and CEO Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss the company filing a modified protocol of their Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus. 

Pourhassan telling Proactive that new protocol is for 75 planned patients in up to 10 centres in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.


 

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

4 days, 8 hours ago

2 min read